RecruitingNot ApplicableNCT06361641

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes-PHEMOP

Sponsor

University Hospital, Angers

Enrollment

70 participants

Start Date

May 29, 2024

Study Type

INTERVENTIONAL

Conditions

Myeloproliferative Neoplasm Polycythemia Vera Primary Myelofibrosis Essential Thrombocythemia

Summary

Prospective study for functional and phenotypic characterization of monocytes in philadelphia-negative myeloproliferative neoplasms

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Monocytes signatures in myeloproliferative neoplasms at diagnosis for people with essential thrombocythemia, myeloproliferative neoplasm, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTMonocytes signatures in myeloproliferative neoplasms at diagnosis

The monocytes signatures will be perform from a peripheral blood sample. The signature will be derived from (i) surface marker expression, (ii) cytokines profiles, (iii) genes expression.

Locations(3)

GOUBAND Agathe

Angers, Maine et Loire, France

BESCOND Charles

Cholet, Maine et Loire, France

TRUCHAN-GRACZYK Malgorzata

Saumur, Maine et Loire, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06361641

Related Trials

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

NCT036309911 location

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

NCT042821871 location

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

NCT0634380521 locations

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

NCT0532019828 locations

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200